Evidence map›Paper›PMID 36044097›Full record

Trial reportActa diabetologica2022

Impact of light therapy on rotating night shift workers: the EuRhythDia study.

Stefano Rizza, Alessio Luzi, Maria Mavilio, Marta Ballanti, Arianna Massimi, Ottavia Porzio, Andrea Magrini, Juliane Hannemann, Rossella Menghini, Jonathan Cridland and 5 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Acta diabetologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Circadian rhythm disruption and endocrine-related tumors.World journal of clinical oncology · 2024
    Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 4 countries.

Stefano RizzaDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy. stefano.rizza@uniroma2.it.
Alessio LuziDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Maria MavilioDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Marta BallantiDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Arianna MassimiDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Ottavia PorzioDepartment of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Andrea MagriniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Juliane HannemannInstitute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Rossella MenghiniDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Jonathan CridlandLUMIE, Cambridge, UK.
Bart StaelsINSERM, CHU Lille, Institut Pasteur de Lille, University of Lille, U1011, EGID, 59000, Lille, France.
Peter J GrantLeeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Rainer H BogerInstitute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Nikolaus MarxDepartment of Cardiology, University Medical Center Aachen, Aachen, Germany.
Massimo FedericiDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.ORCID http://orcid.org/0000-0003-4989-5194
University of Rome Tor Vergata · ITUniversität Hamburg · DEInserm · FRLumen (United Kingdom) · GBUniversity of Leeds · GB

Funding

FP7 Science in Society 278397
6 · The paper itself

Abstract

aimsDisturbances in circadian rhythms may promote cardiometabolic disorders in rotating night shift workers (r-NSWs). We hypothesized that timed light therapy might reverse disrupted circadian rhythms and glucose intolerance observed among r-NSWs).

methodsR-NSWs were randomly assigned to a protocol that included 12 weeks on followed by 12 weeks off light therapy (n = 13; 6 men; mean age, 39.5 ± 7.3 years) or a no-treatment control group (n = 9; 3 men; mean age 41.7 ± 6.3 years). Experimental and control participants underwent identical metabolic evaluations that included anthropometric, metabolic (including oral glucose tolerance tests), lipid, and inflammation-associated parameters together with an assessment of sleep quality and expression of circadian transcription factors REV-ERBα and BMAL1 in peripheral blood mononuclear cells (PBMCs) at baseline, 12 weeks, and 24 weeks of the protocol.

resultsTwelve weeks of warm white-light exposure (10,000 lx at 35 cm for 30 min per day) had no impact on sleep, metabolic, or inflammation-associated parameters among r-NSWs in the experimental group. However, our findings revealed significant decreases in REV-ERBα gene expression (p = 0.048) and increases in the REV-ERBα/BMAL1 ratio (p = 0.040) compared to baseline in PBMCs isolated from this cohort. Diminished expression of REV-ERBα persisted, although the REV-ERBα/BMAL1 ratio returned to baseline levels after the subsequent 12-day wash-out period.

conclusionsOur results revealed that intermittent light therapy had no impact on inflammatory parameters or glucose tolerance in a defined cohort of r-NSWs. However, significant changes in the expression of circadian clock genes were detected in PBMCs of these subjects undergoing light therapy.

Indexed as

ARNTL Transcription FactorsNuclear Receptor Subfamily 1, Group D, Member 1AdultCircadian RhythmGlucoseHumansInflammationLeukocytes, MononuclearLipidsMaleMiddle AgedPhototherapyARNTL Transcription FactorsGlucoseLipidsNuclear Receptor Subfamily 1, Group D, Member 1BMAL1Clock genesDiabetesLight therapyNight shift workREV-ERBs

Identifiers

PMID36044097
PMCPMC9430001
OpenAlexW4293834837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.